Skip to main content

Stem Cells for Relevant Efficient Extended and Normalized Toxicology

Objective

In the development of products for use by humans it is vital to identify compounds with toxic properties at an early stage of their development, to avoid spending time and resource on unsuitable and potentially unsafe candidate products. Human pluripotent stem cell lines offer a unique opportunity to develop a wide variety of human cell-based test systems because they may be expanded indefinitely and triggered to differentiate into any cell type. SCR&Tox aims at making use of these two attributes to provide in vitro assays for predicting toxicity of pharmaceutical compounds and cosmetic ingredients. The consortium has been designed to address all issues related with biological and technological resources to meet that goal. In order to demonstrate the value of pluripotent stem cells for toxicology, the consortium will focus on four complementary aspects: Relevance –i.e. establishing and maintaining discrete cell phenotypes over long-term cultures; providing large versatility to adapt to assays of specific pathways. Efficiency –for i) automated cell production and differentiation, ii) cell engineering for differentiation and selection iii) multi-parametric toxicology using functional genomic, proteomic and bioelectronics. Extension –i.e. i) scalability through production of cells and technologies for industrial-scale assays, and ii) diversity of phenotypes (5 different tissues), and of genotypes (over 30 different donors). Normalization –validation and demonstration of reproducibility and robustness of cell-based assays on industrial-scale platforms, to allow for secondary development in the pharmaceutical and cosmetic industry. SCR&Tox will be intricately associated to other consortia of the “Alternative Testing” call, sharing biological, technological and methodological resources. Proof of concept of the proposed pluripotent stem cell-based assays for toxicology will be provided on the basis of toxicity pathways and test compounds identified by other consortia.

Call for proposal

FP7-HEALTH-2010-Alternative-Testing
See other projects for this call

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Address
Rue De Tolbiac 101
75654 Paris
France

See on map

Activity type
Research Organisations
Administrative Contact
Laurie Louis-Joseph (Mrs.)
EU contribution
€ 1 101 929,33

Participants (14)

UNIVERSITATSKLINIKUM BONN
Germany
EU contribution
€ 399 218
Address
Venusberg-campus 1
53127 Bonn

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Beate Becker (Ms.)
Takara Bio Europe AB
Sweden
EU contribution
€ 612 269
Address
Arvid Wallgrens Backe
413 46 Göteborg

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Karina Lövstedt (Ms.)
CELLECTIS SA

Participation ended

France
EU contribution
€ 171 030,56
Address
Rue Jean Antoine De Baif 12
75013 Paris

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Patricia Sosa Navarro (Ms.)
CXR Biosciences Limited
United Kingdom
EU contribution
€ 237 205,77
Address
James Lindsay Place
DD1 5JJ Dundee

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Gavin Hands (Mr.)
UNIVERSITAET LEIPZIG
Germany
EU contribution
€ 293 322,88
Address
Ritterstrasse 26
04109 Leipzig

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Gerhard Fuchs (Mr.)
CIT SAS
France
EU contribution
€ 236 858,94
Address
Miserey
27005 Evreux

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Patrick Spies (Mr.)
LABCORP EARLY DEVELOPMENT LABORATORIES LIMITED
United Kingdom
EU contribution
€ 236 576,35
Address
Otley Road
HG3 IPY Harrogate

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Robert Greenhalf (Mr.)
JRC -JOINT RESEARCH CENTRE- EUROPEAN COMMISSION
Belgium
EU contribution
€ 313 426,65
Address
Rue De La Loi 200
1049 Brussels

See on map

Activity type
Research Organisations
Administrative Contact
Iain Formosa (Mr.)
ASTRAZENECA AB
Sweden
EU contribution
€ 226 936,70
Address
Vastra Maelarhamnen
151 85 Sodertaelje

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Per Hall (Mr.)
KAROLINSKA INSTITUTET
Sweden
EU contribution
€ 267 996,96
Address
Nobels Vag 5
17177 Stockholm

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Eva Gipperth (Ms.)
AVANTEA srl
Italy
EU contribution
€ 155 570
Address
Via Cabrini 12
26100 Cremona

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Anna D Apolito (Ms.)
HEALTH PROTECTION AGENCY HPA

Participation ended

United Kingdom
EU contribution
€ 119 454,18
Address
Buckingham Palace Road 151
SW1W 9SZ London

See on map

Activity type
Research Organisations
Administrative Contact
Amanda King (Ms.)
INSERM TRANSFERT SA
France
EU contribution
€ 160 800
Address
Rue Watt 7
75013 Paris

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Louis Jammayrac (Mr.)
Department of Health
United Kingdom
EU contribution
€ 167 404,68
Address
Quarry House, Quarry Hill
LS2 7UE Leeds

See on map

Activity type
Research Organisations
Administrative Contact
Amanda King (Mrs.)